
Michael Orth
@molradonc_tub
Principal Investigator in Radiation Oncology at Eberhard Karls University Tübingen (Germany)
ID: 1657443605399601153
https://profile.medizin.uni-tuebingen.de/contacts/uid/5443 13-05-2023 17:52:13
13 Tweet
67 Followers
288 Following


Ulrich-Hagen medal awarded to Horst Zitzelsberger from Helmholtz Munich | @HelmholtzMunich: 35 years cutting-edge radiobiological research, continuous implementation of new expertises and methodologies, superengaged promotion of young talents, and just a very nice guy to work with. Congrats Horst!



Getting one scholarship from the Promotionskolleg 2024-2 of Faculty of Medicine Tuebingen is nice, but getting two for promoting two highly promising medical students is great🤩🥳. Thanks to the committee and to Prof. Maximilian Niyazi Max Niyazi and Prof. Cihan Gani Cihan Gani for their support

Join us in Tübingen for the first edition of the Nikolaus-Symposium! Fantastic line-up of international speakers! Alison Tree 💙 Stefanie Corradini 🌟 @IvanVogelius Stephanie Tanadini-Lang Deutsche Gesellschaft für Radioonkologie e.V. ESTRO Max Niyazi Simon Boeke @D_Thorwarth Uniklinikum Tübingen UKT Radiation Oncology Faculty of Medicine Tuebingen


What a great day! Yesterday we went live with Comprehensive Motion Management for our MR-Linac! Thanks to everybody who made this possible! Simon Boeke Marcel Nachbar @D_Thorwarth Max Niyazi Monica Lo Russo Elekta MR-Linac Consortium DFG

We currently have a Job Opening for a PostDoc in the Department of Radiation Oncology with Scientific Focus on Preclinical and Translational Radiobiology. Applications Welcome! UKT Radiation Oncology Michael Orth


Prof. Cihan Gani from Tübingen, Germany, shared some exciting early results from his study on MR-guided adaptive dose escalation for rectal cancer at the recent MR-Linac Consortium meeting in Singapore. Cihan Gani Bowel Cancer UK BowelCancerAustralia Colon Cancer Foundation

New paper from our groups UKT Radiation Oncology, Max Niyazi, Michael Orth, LMU Radiation Oncology, Helmholtz Munich | @HelmholtzMunich providing a preclinical rationale for implementing #Bevacizumab in radio(chemo)therapy-treated glioblastoma patients to reduce radionecrosis levels. doi.org/10.1002/adtp.2…
